Aviado · Research
Longevity Daily
Saturday, May 2, 2026
Listen
Today's Brief
The first trial combining rapamycin with exercise returned disappointing results, but Peter Attia's breakdown of why the protocol may have failed the drug — not vice versa — is the most important longevity read of the week. Aviado Research makes the case that personalizing your DHA dose around your Omega-3 Index could mean the difference between a working supplement and an expensive placebo. An RCT finds 8 weeks of pickleball reversed pre-frailty in 42% of older adults, and new Aging Cell research links environmental antibiotic residues to accelerated gut biological aging. The FDA's push toward real-time clinical trials rounds out a data-dense edition.
10 stories2 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
The Next Alzheimer's Breakthrough Needs More Than Science to Succeed
Wired profiles John Hardy, the geneticist whose work established the amyloid hypothesis, and gets a candid assessment of why drugs targeting amyloid plaques haven't delivered the outcomes early research promised. Hardy's key insight: antibodies designed to prevent amyloid deposits work very differently in asymptomatic people than in patients who already carry significant plaque burden — a distinction that explains years of disappointing late-stage trial results. For you, this matters because the next wave of Alzheimer's interventions is shifting toward earlier detection and broader biological targets well beyond amyloid alone.
Read more →Supplements & Compounds
Your DHA Supplement May Not Be Reaching Your Brain — Your Omega-3 Index Tells You Why
Taking the same DHA dose as someone else can produce three times better results — or barely work at all — depending on your starting Omega-3 Index. New Aviado Research analysis finds that below a 5% index, you likely need 1,000 mg of DHA daily in phospholipid form (with meals) to meaningfully raise brain levels; at 6–7%, 500 mg may be sufficient. The practical step: test your Omega-3 Index first, dose based on your result, then retest at 12 weeks to confirm you've hit the optimal 8% target.
Read the full Aviado analysis →Fatty15 Is Making Bold Anti-Aging Claims — A McGill Scientist Weighs the Evidence
"Fatty15" — a supplement built around pentadecanoic acid (C15:0), a saturated fatty acid found naturally in dairy fat — is positioning itself as a longevity breakthrough inspired by research on long-lived dolphins. McGill University's Office for Science and Society takes a close look at the actual evidence: early mechanistic findings are genuinely interesting, but human data supporting its anti-aging claims remains thin. A useful evidence check before adding another item to your stack.
Read more →Research & Papers
Disappointing Results from the First Rapamycin-Plus-Exercise Trial — But Attia Isn't Giving Up on Rapamycin
The first randomized trial to combine rapamycin with an exercise protocol in humans failed to show the synergistic benefits many longevity researchers anticipated — a meaningful setback given how much excitement these two interventions generate together. Peter Attia digs into the trial mechanics, explaining why the specific dosing regimen and the timing of rapamycin relative to training sessions may have undermined the result rather than reflecting the drug's true potential. His conclusion: rapamycin and exercise can work against each other at the molecular level if combined carelessly, but a single negative trial doesn't close the book on rapamycin as a geroprotector. If you're following the rapamycin story — or considering it yourself — this analysis is essential reading.
Read more →Antibiotic Residues in Food and Water Are Accelerating Gut Biological Aging, Aging Cell Study Finds
Chronic low-level exposure to enrofloxacin — a veterinary antibiotic routinely detected in food and water supplies — accelerates gut biological aging via mitochondrial dysfunction, increasing gut permeability, inflammation, and microbiome disruption, according to research published in Aging Cell. A human cross-sectional analysis found antibiotic use was associated with measurably increased biological age and higher rates of digestive issues in middle-aged and older adults. The mitigating factor: higher dietary antioxidant capacity and a gut microbiota-supporting dietary pattern significantly reduced the effect — adding to the case for consistent diet quality as a defense against environmental aging accelerants. Note: primary mechanistic findings are from zebrafish models, not human trials.
Read more →Lifestyle & Nutrition
Eric Topol Draws the Line Between Longevity Science and the 'Super Aging' Grift
Physician-researcher Eric Topol joins NPR to break down what the evidence actually supports for healthy aging versus what the industry is overselling — and his hierarchy may surprise you. Resistance training tops his list (specifically not just general exercise), alongside sleep optimization and vaccines, while he's openly skeptical of most large supplement regimens and many trendy interventions amplified by social media. For health-conscious readers navigating an increasingly noisy longevity marketplace, Topol's evidence-based framework is a useful recalibration.
Read more →8 Weeks of Pickleball Reverses Pre-Frailty in 42% of Older Adults — New RCT
A randomized controlled trial of 72 pre-frail older adults (median age 67) found that those assigned to supervised pickleball sessions for 8 weeks were more than five times more likely to transition out of pre-frailty than controls: 42% vs. 8% (p<0.001). Functional fitness improved significantly across multiple measures — chair stands, arm curls, and 6-minute walk distance — alongside reduced sedentary time and better mental health scores. Pre-frailty is the highest-value intervention window before full frailty sets in, and pickleball's combination of social engagement, lateral movement, and aerobic demand may explain results that outperform conventional exercise programs.
Read more →Can Spending More Actually Buy You a Longer Life? The New York Times Investigates
As the longevity wellness industry continues to expand, The New York Times examines whether the growing consumer appetite for expensive healthspan interventions — supplements, biomarker testing, coaching, and clinics — is backed by proportionate evidence. The piece interrogates the concept of "healthspan" itself, a term coined in the 1980s that now sits at the center of a multi-billion dollar commercial ecosystem. A useful reality check for anyone evaluating where their health spending actually delivers meaningful return.
Read more →Industry & Policy
FDA's Real-Time Clinical Trial Push Could Compress Drug Approval Timelines — If It Works
The FDA has taken concrete early steps toward "real-time clinical trials" — a model where data flows directly to regulators as it's collected, rather than in a final submission after trial completion. AstraZeneca and Amgen are the first participants, currently testing drugs for lymphoma and lung cancer under this framework. If the model scales, it could meaningfully accelerate approval timelines for longevity-relevant therapies currently advancing through development.
Read more →How Mel Gibson and a Hollywood Campaign Shaped 30 Years of Unregulated Supplements
Inc. traces the 1994 campaign that blocked FDA oversight of dietary supplements — a lobbying effort that enlisted Mel Gibson and other celebrities to pressure Congress, ultimately producing the Dietary Supplement Health and Education Act (DSHEA). The law effectively prevents the FDA from removing unsafe or ineffective products from shelves before they cause harm, creating the lightly regulated supplement landscape that still exists today. For anyone buying supplements, understanding DSHEA explains exactly why third-party certifications like NSF, USP, and Informed Sport matter so much when evaluating what's actually in your bottle.
Read more →